| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | TDO2 |
| Uniprot No | P48775 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-406aa |
| 氨基酸序列 | MSGCPFLGNNFGYTFKKLPVEGSEEDKSQTGVNRASKGGLIYGNYLHLEK VLNAQELQSETKGNKIHDEHLFIITHQAYELWFKQILWELDSVREIFQNG HVRDERNMLKVVSRMHRVSVILKLLVQQFSILETMTALDFNDFREYLSPA SGFQSLQFRLLENKIGVLQNMRVPYNRRHYRDNFKGEENELLLKSEQEKT LLELVEAWLERTPGLEPHGFNFWGKLEKNITRGLEEEFIRIQAKEESEEK EEQVAEFQKQKEVLLSLFDEKRHEHLLSKGERRLSYRALQGALMIYFYRE EPRFQVPFQLLTSLMDIDSLMTKWRYNHVCMVHRMLGSKAGTGGSSGYHY LRSTVSDRYKVFVDLFNLSTYLIPRHWIPKMNPTIHKFLYTAEYCDSSYF SSDESD |
| 预测分子量 | 48 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于TDO2重组蛋白的3篇参考文献示例(注：文献信息为模拟示例，实际引用请核实原文)：
---
1. **文献名称**: "Expression and Purification of Recombinant Human TDO2 in Escherichia coli for Structural Studies"
**作者**: Smith A, et al.
**摘要**: 本研究报道了人源TDO2在大肠杆菌中的高效重组表达与纯化方法，分析了其酶动力学特性，并通过X射线晶体学解析了TDO2的蛋白结构，为靶向TDO2的药物设计提供了结构基础。
---
2. **文献名称**: "Functional Characterization of Recombinant TDO2 in Cancer Immunosuppression"
**作者**: Zhang L, et al.
**摘要**: 通过体外重组TDO2蛋白实验，验证了其在肿瘤微环境中通过降解色氨酸促进免疫抑制的作用，并发现其调控T细胞功能的具体机制，提示TDO2作为癌症治疗靶点的潜力。
---
3. **文献名称**: "Development of a High-Throughput Screening Assay for TDO2 Inhibitors Using Recombinant Protein"
**作者**: Johnson R, et al.
**摘要**: 利用重组TDO2蛋白建立了一种高通量筛选平台，成功鉴定了多个新型小分子抑制剂，并验证了其对TDO2酶活性的抑制作用，为抗肿瘤药物研发提供了工具。
---
如需实际文献，建议通过PubMed或Web of Science检索关键词 **"TDO2 recombinant protein"** 或 **"Tryptophan 2.3-dioxygenase expression"** 获取最新研究。
**Background of TDO2 Recombinant Protein**
Tryptophan 2.3-dioxygenase (TDO2) is a heme-containing enzyme that catalyzes the first and rate-limiting step of tryptophan metabolism, converting tryptophan into N-formylkynurenine. This pathway, known as the kynurenine pathway, plays a critical role in regulating immune responses, neurotransmitter synthesis, and energy homeostasis. TDO2 is primarily expressed in the liver but is also detected in the brain, placenta, and certain cancer cells. Its activity influences systemic tryptophan levels, indirectly modulating immune tolerance via depletion of local tryptophan and accumulation of immunosuppressive metabolites like kynurenine. Dysregulation of TDO2 has been implicated in cancer progression, neurodegenerative disorders (e.g., Alzheimer’s disease), and mood disorders, making it a therapeutic target of interest.
Recombinant TDO2 protein is engineered through molecular cloning techniques, where the *TDO2* gene is expressed in heterologous systems like *E. coli*, yeast, or mammalian cells. This allows large-scale production of purified, functional TDO2 for research and drug discovery. Unlike its homolog IDO1 (indoleamine 2.3-dioxygenase 1), TDO2 exhibits distinct substrate specificity, tissue distribution, and regulatory mechanisms. Recombinant TDO2 enables detailed biochemical studies, including enzyme kinetics, inhibitor screening, and structural analysis (e.g., X-ray crystallography), to elucidate its role in disease contexts. It also aids in developing TDO2-specific inhibitors, which are explored as potential anticancer or neuroprotective agents. Additionally, recombinant TDO2 serves as a tool to study cross-talk between metabolic and immune pathways, offering insights into therapeutic strategies targeting the kynurenine axis.
×
